NCT05296044

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

This Study Evaluates the Addition of Dapagliflozin in the Treatment of Type 2 Diates With Metformin and JT-003 Combination Therapy.

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 245 (estimated)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of JT-003 Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	JT-003	Subjects take the investigational products once a day for 24 weeks.
DRUG	JT-003 Placebo	Subjects take the investigational products once a day for 24 weeks.

Timeline

• Start date: 2022-04-05
• Primary completion: 2023-10-31
• Completion: 2024-02-28
• First posted: 2022-03-25
• Last updated: 2022-03-25

Locations

1 site across 1 country: South Korea